medigraphic.com
ISSN 2225-4676 (Electronic)

2012, Number 2

<< Back Next >>

Rev Cubana Neurol Neurocir 2012; 2 (2)

Cerebellar glioblastoma multiforme

Lacerda GÁJ, Díaz AJA, Pérez LS, Martín CD, Mirabal GY, Tacas GN

Language: Spanish
References: 11
Page: 141-143
PDF size: 307.42 Kb.


ABSTRACT

Introduction: Glioblastoma multiforme is the most common malignant primary brain tumor in adults. It is usually centered in the deep white matter of the cerebral hemispheres in supratentorial location. Cerebellar glioblastoma multiforme is infrequent with an incidence of 0.24%. This article informs about one case with cerebellar glioblastoma multiforme surgically treated in “Roberto Rodríguez” General Docent Hospital of Morón (Ciego de Ávila).
Case report: A young patient with 39 years old was operated on by glioblastoma multiforme of the left cerebellum hemisphere. She has a satisfactory evolution after total surgical resection with adjuvant post–surgical radiotherapy and type hR3a monoclonal antibody therapy.
Conclusions: Cerebellar glioblastoma multiforme is a rare tumor with a different biological behavior from those centered in supratentorial cerebral hemispheres.


REFERENCES

  1. Salcman M. Glioblastoma and malignant astrocytoma. En: Kaye AH, Laws Jr ER, eds. Brain tumors. 1ra ed. Hong Kong: Churchill Livingstone; 1995. p. 449–77.

  2. Sanai N, Berger MS. Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics 2009;6:478–86.

  3. Nogués Bara P, Aguas Valiente J, Pallarés Quixal J. Glioblastoma cerebeloso. Caso clínico. Oncología (Barc.). [Internet]. 2006 [citado 2012 Mar 2]; 29(3):45–9. En: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0378–48352006000300006&lng=en http://dx.doi.org/10.4321/S0378–48352006000300006

  4. Lan F, Yue X, Han L, Yuan X, Shi Z, Huang K, et al. Antitumor effect of aspirin in glioblastoma cells by modulation of β–catenin/T–cell factor–mediated transcriptional activity. J Neurosurg. 2011;115(4):780–8.

  5. Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. J Neurosurg. 2011;115(2):220–9.

  6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

  7. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79–88.

  8. Dixit S, Hingorani M, Achawal S, Scott I. The sequential use of carmustine wafers (Gliadel®) and post–operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg. 2011;25(4):459–69.

  9. Grahovac G, Tomac D, Lambasa S, Zoric A, Habek M. Cerebellar glioblastomas: pathophysiology, clinical presentation and management. Acta Neurochir (Wien). 2009;151(6):653–7.

  10. Hegedus K, Molnar P. Primary cerebellar glioblastoma multiforme with an unusually long survival. J Neurosurg. 1983;58:589–92.

  11. Kaur G, Bloch O, Jian BJ, Kaur R, Sughrue ME, Aghi MK, et al. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J Neurosurg. 2011;115(4):754–9.




2020     |     www.medigraphic.com